Sun Pharmaceutical Industries’ skin cancer drug Unloxcyt just picked up something that can matter almost as much as an approval: a stronger place in the treatment guidelines U.S. oncologists and insurers actually lean on.

On October 20, Sun Pharma (NSE: SUNPHARMA; BSE: 524715) said the National Comprehensive Cancer Network (NCCN) has elevated Unloxcyt (cosibelimab-ipdl) to a Category 2A recommended option for locally advanced cutaneous squamous cell carcinoma (laCSCC). That covers patients whose cancer can’t be cured with surgery or radiation. The drug already held a Category 2A listing for metastatic disease, assigned in 2025.

No new trial. No new FDA action. So why care? Because NCCN listings feed straight into how payers write coverage policies and prior-authorization rules. For a drug that only became available in the U.S. in January 2026, entering a market where rivals have years of head start, that can shape how quickly prescriptions get approved.

What the NCCN Update Says, and What It Doesn’t

NCCN is an alliance of 34 U.S. cancer centers, and it grades every recommendation it makes. Category 2A means the expert panel reached uniform consensus that a treatment is appropriate, based on lower-level evidence such as single-arm studies rather than randomized trials.

There’s a wrinkle. Sun Pharma’s headline calls this a “preferred” designation. The body of its own release only ever describes it as a recommended option. NCCN separates preferred regimens from other recommended ones, and the gap is meaningful. BioTech Stocks Daily could not independently confirm which tier Unloxcyt now occupies, because the full guideline text sits behind an NCCN login.

The Data Behind the Decision

According to Sun Pharma, NCCN reviewed results from the pivotal CK-301-101 study. In the locally advanced group, 55% of patients saw their tumors shrink measurably (the objective response rate), and 26% had no detectable disease left (a complete response). At a median follow-up of 24.1 months, the median duration of response still had not been reached.

The release skips one basic number: how many patients that was. Independent reporting on the FDA label shows the locally advanced cohort had just 31 people. That’s a small group. And the study had no comparison arm.

A bigger, more recent dataset exists. At the 2026 ASCO Annual Meeting, an updated locally advanced cohort of 64 patients showed a 50% response rate and a complete response rate of about 27%, at 31 months of median follow-up. Still solid. It’s also a few points lower on the headline measure than the figure Sun chose to feature.

One more detail worth knowing. The approved dose is 1,200 mg every three weeks. The locally advanced patients in the pivotal study were actually treated at 800 mg every two weeks, according to the published study abstract.

Safety in an Older Patient Group

Sun Pharma says fewer than 1% of patients had a severe (Grade 3 to 5) immune-mediated side effect, with no Grade 4 or 5 events. That point carries weight here. People with this cancer skew elderly, with a median age of 76 in the updated cohort, and many manage other illnesses at the same time. Unloxcyt’s label still carries the standard checkpoint-inhibitor warnings for immune reactions that can affect the lungs, liver, colon, hormone glands, and other organs.

“First and Only,” With a Footnote

Sun Pharma calls Unloxcyt the first and only FDA-approved PD-L1-blocking antibody for advanced CSCC. As worded, that’s accurate. It’s also narrow.

Two drugs that block the partner receptor, PD-1, got there first. Regeneron’s (Nasdaq: REGN) Libtayo (cemiplimab) won FDA approval for advanced CSCC in September 2018, then added an adjuvant (post-surgery) approval for high-risk patients in October 2025. Merck’s (NYSE: MRK) Keytruda (pembrolizumab) was cleared for locally advanced CSCC in July 2021. Both have appeared as preferred systemic options in past versions of NCCN’s guidelines.

For rough context, Keytruda’s locally advanced cohort posted a 50% response rate with a 17% complete response rate in 54 patients. Libtayo’s initial approval showed a 49% response rate in 33 locally advanced patients. These numbers come from separate single-arm studies with different patients and different follow-up times. None of the drugs has been tested head-to-head against another, so the comparison is suggestive at best.

Sun Pharma’s case leans on mechanism. Dr. Francis Worden of the University of Michigan Rogel Cancer Center, quoted in the release, credits the drug’s ability to recruit a second arm of the immune system, known as antibody-dependent cellular cytotoxicity, for its results. That’s his view and the company’s, not a proven explanation. The release doesn’t say whether Dr. Worden has any financial relationship with Sun Pharma.

How Sun Pharma Got the Drug

Sun Pharma didn’t develop cosibelimab. It bought Checkpoint Therapeutics in May 2025 for $4.10 per share in cash, plus a contingent value right worth up to $0.70 more if the drug wins approval in the European Union or certain European countries before set deadlines. Fortress Biotech (Nasdaq: FBIO), which founded Checkpoint, receives a 2.5% royalty on future Unloxcyt net sales.

What Investors Aren’t Told

The release offers no sales figures, no count of patients treated, and no estimate of what the guideline change might add to revenue. Sun Pharma says its innovative medicines business makes up about 20% of company sales, but it doesn’t break out Unloxcyt. Its figures of roughly 40,000 U.S. cases progressing to advanced disease each year, and nearly 15,000 deaths, come without a cited source.

A guideline listing opens a door. Whether oncologists walk through it, with Libtayo and Keytruda long entrenched, is something Sun Pharma’s coming earnings reports will have to show.

Sources

• Sun Pharma: Sun Pharma Announces UNLOXCYT (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for laCSCC, PRNewswire, October 20, 2026. Primary source release.
• OncLive: Updated Cosibelimab Label Reflects Long-Term Data in Advanced CSCC, cited for the 31-patient size of the locally advanced cohort behind the 55% and 26% figures, which the release did not disclose.
• OncLive: Updated Locally Advanced Cohort Data From the CK-301-101 Study, cited for the expanded 64-patient cohort data presented at the 2026 ASCO Annual Meeting, including the median patient age of 76.
• Efficacy and Safety of Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma (study abstract, Mendeley Data), cited for the 800 mg every-two-weeks dosing used in the locally advanced cohort.
• Sun Pharma Announces Availability of UNLOXCYT for Advanced CSCC in US (BioSpectrum), cited for the January 2026 U.S. commercial availability of Unloxcyt.
• Sun Pharma Completes Its Acquisition of Checkpoint Therapeutics (1stOncology), cited for the May 2025 completion date and the $4.10 per share plus CVR deal terms.
• Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics, cited for the CVR’s European approval conditions and Fortress Biotech’s 2.5% royalty on Unloxcyt net sales.
• ESMO: FDA Approves Cemiplimab-rwlc for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma, cited for Libtayo’s September 2018 approval and its 49% response rate in 33 locally advanced patients.
• U.S. FDA: FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma, cited for Libtayo’s October 2025 adjuvant approval.
• Merck: FDA Approves Expanded Indication for KEYTRUDA in Locally Advanced Cutaneous Squamous Cell Carcinoma, cited for Keytruda’s July 2021 approval and its 50% response rate and 17% complete response rate in 54 patients.
• Current Oncology Reports: Systemic Therapies for Locally Advanced and Metastatic Non-Melanoma Skin Cancers, cited for cemiplimab and pembrolizumab being listed as preferred systemic regimens in prior NCCN guideline versions.

Editorial Disclosure

This article is based on a press release issued by Sun Pharmaceutical Industries Limited on October 20, 2026 regarding the National Comprehensive Cancer Network (NCCN) guideline status of UNLOXCYT (cosibelimab-ipdl). Securities and corporate structures discussed: Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA; BSE: 524715), Fortress Biotech, Inc. (Nasdaq: FBIO, as royalty holder on UNLOXCYT net sales), Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN), and Merck & Co., Inc. (NYSE: MRK). BioTech Stocks Daily has not received, nor will it accept, any compensation, direct or indirect, from Sun Pharma, Fortress Biotech, Regeneron, Merck, or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. Details on the pivotal study’s cohort size, the updated 2026 ASCO data, study dosing, competing therapies, prior NCCN listings, and the Checkpoint Therapeutics acquisition were drawn from the independent sources cited above, since the original release did not address them. Statements regarding future guideline updates, payer coverage, commercial uptake, revenue contribution, and contingent value right milestones are forward-looking statements. They involve substantial risks, regulatory uncertainties, and market variables; actual clinical, commercial, and financial outcomes may differ materially. Pharmaceutical investments carry significant financial risk. Commercial results for approved drugs are subject to competition, payer decisions, and regulatory developments, which can result in the loss of invested capital. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. Furthermore, this content is not medical advice; patients and healthcare providers should consult appropriate clinical professionals for medical guidance.

For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, please see our full DISCLAIMER.